300 related articles for article (PubMed ID: 10369069)
1. Increased AP-1 activity in drug resistant human breast cancer MCF-7 cells.
Daschner PJ; Ciolino HP; Plouzek CA; Yeh GC
Breast Cancer Res Treat; 1999 Feb; 53(3):229-40. PubMed ID: 10369069
[TBL] [Abstract][Full Text] [Related]
2. Negative regulation of MDR1 promoter activity in MCF-7, but not in multidrug resistant MCF-7/Adr, cells by cross-coupled NF-kappa B/p65 and c-Fos transcription factors and their interaction with the CAAT region.
Ogretmen B; Safa AR
Biochemistry; 1999 Feb; 38(7):2189-99. PubMed ID: 10026303
[TBL] [Abstract][Full Text] [Related]
3. Survivin transcription is associated with P-glycoprotein/MDR1 overexpression in the multidrug resistance of MCF-7 breast cancer cells.
Liu F; Liu S; He S; Xie Z; Zu X; Jiang Y
Oncol Rep; 2010 May; 23(5):1469-75. PubMed ID: 20372866
[TBL] [Abstract][Full Text] [Related]
4. PSC833, cyclosporine analogue, downregulates MDR1 expression by activating JNK/c-Jun/AP-1 and suppressing NF-kappaB.
Bark H; Choi CH
Cancer Chemother Pharmacol; 2010 May; 65(6):1131-6. PubMed ID: 19763573
[TBL] [Abstract][Full Text] [Related]
5. Two proximal activating protein-1-binding sites are sufficient to stimulate transcription of the ovine follicle-stimulating hormone-beta gene.
Strahl BD; Huang HJ; Pedersen NR; Wu JC; Ghosh BR; Miller WL
Endocrinology; 1997 Jun; 138(6):2621-31. PubMed ID: 9165057
[TBL] [Abstract][Full Text] [Related]
6. Activation and inhibition of the AP-1 complex in human breast cancer cells.
Chen TK; Smith LM; Gebhardt DK; Birrer MJ; Brown PH
Mol Carcinog; 1996 Mar; 15(3):215-26. PubMed ID: 8597534
[TBL] [Abstract][Full Text] [Related]
7. Involvement of activator protein-1 (AP-1) in induction of apoptosis by vitamin E succinate in human breast cancer cells.
Zhao B; Yu W; Qian M; Simmons-Menchaca M; Brown P; Birrer MJ; Sanders BG; Kline K
Mol Carcinog; 1997 Jul; 19(3):180-90. PubMed ID: 9254885
[TBL] [Abstract][Full Text] [Related]
8. CCAAT/enhancer-binding protein beta (nuclear factor for interleukin 6) transactivates the human MDR1 gene by interaction with an inverted CCAAT box in human cancer cells.
Chen KG; Sale S; Tan T; Ermoian RP; Sikic BI
Mol Pharmacol; 2004 Apr; 65(4):906-16. PubMed ID: 15044620
[TBL] [Abstract][Full Text] [Related]
9. Preventing chemoresistance of human breast cancer cell line, MCF-7 with celecoxib.
Chen C; Shen HL; Yang J; Chen QY; Xu WL
J Cancer Res Clin Oncol; 2011 Jan; 137(1):9-17. PubMed ID: 20229271
[TBL] [Abstract][Full Text] [Related]
10. MDR1 promoter hypermethylation in MCF-7 human breast cancer cells: changes in chromatin structure induced by treatment with 5-Aza-cytidine.
David GL; Yegnasubramanian S; Kumar A; Marchi VL; De Marzo AM; Lin X; Nelson WG
Cancer Biol Ther; 2004 Jun; 3(6):540-8. PubMed ID: 15034303
[TBL] [Abstract][Full Text] [Related]
11. Role of FoxO1 activation in MDR1 expression in adriamycin-resistant breast cancer cells.
Han CY; Cho KB; Choi HS; Han HK; Kang KW
Carcinogenesis; 2008 Sep; 29(9):1837-44. PubMed ID: 18390843
[TBL] [Abstract][Full Text] [Related]
12. Regulation of MDR1 promoter activity in human breast carcinoma cells by protein kinase C isozymes alpha and theta.
Gill PK; Gescher A; Gant TW
Eur J Biochem; 2001 Aug; 268(15):4151-7. PubMed ID: 11488907
[TBL] [Abstract][Full Text] [Related]
13. Co-suppression of MDR1 (multidrug resistance 1) and GCS (glucosylceramide synthase) restores sensitivity to multidrug resistance breast cancer cells by RNA interference (RNAi).
Zhang X; Li J; Qiu Z; Gao P; Wu X; Zhou G
Cancer Biol Ther; 2009 Jun; 8(12):1117-21. PubMed ID: 19502811
[TBL] [Abstract][Full Text] [Related]
14. Regulation of the rat atrial natriuretic peptide gene after acute imposition of left ventricular pressure overload.
Cornelius T; Holmer SR; Müller FU; Riegger GA; Schunkert H
Hypertension; 1997 Dec; 30(6):1348-55. PubMed ID: 9403552
[TBL] [Abstract][Full Text] [Related]
15. AP-1 activation and altered AP-1 composition in association with increased phosphorylation and expression of specific Jun and Fos family proteins induced by vinblastine in KB-3 cells.
Berry A; Goodwin M; Moran CL; Chambers TC
Biochem Pharmacol; 2001 Sep; 62(5):581-91. PubMed ID: 11585055
[TBL] [Abstract][Full Text] [Related]
16. Co-ordinate loss of protein kinase C and multidrug resistance gene expression in revertant MCF-7/Adr breast carcinoma cells.
Budworth J; Gant TW; Gescher A
Br J Cancer; 1997; 75(9):1330-5. PubMed ID: 9155054
[TBL] [Abstract][Full Text] [Related]
17. Functional study of the novel multidrug resistance gene HA117 and its comparison to multidrug resistance gene 1.
Zhao L; Jin X; Xu Y; Guo Y; Liang R; Guo Z; Chen T; Sun Y; Ding X
J Exp Clin Cancer Res; 2010 Jul; 29(1):98. PubMed ID: 20642825
[TBL] [Abstract][Full Text] [Related]
18. Differences between drug-sensitive and -resistant human leukemic CEM cells in c-jun expression, AP-1 DNA-binding activity, and formation of Jun/Fos family dimers, and their association with internucleosomal DNA ladders after treatment with VM-26.
Kim R; Beck WT
Cancer Res; 1994 Sep; 54(18):4958-66. PubMed ID: 8069863
[TBL] [Abstract][Full Text] [Related]
19. Fos and Jun inhibit estrogen-induced transcription of the human progesterone receptor gene through an activator protein-1 site.
Petz LN; Ziegler YS; Schultz JR; Nardulli AM
Mol Endocrinol; 2004 Mar; 18(3):521-32. PubMed ID: 14684847
[TBL] [Abstract][Full Text] [Related]
20. Expression of c-fos and c-jun proteins and AP-1 binding activity during cell cycle progression of HL60 cells and phytohemagglutinin-stimulated lymphocytes.
Tay DL; Hoffbrand AV; Wickremasinghe GR
Exp Hematol; 1996 Feb; 24(2):277-84. PubMed ID: 8641353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
